Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar
Dow Jones
Feb 12
Novocure said the Food and Drug Administration approved its Optune Pax product to treat people with certain pancreatic cancers.
The drug can be used for adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel, the Swiss biopharmaceutical company said Wednesday.
Optune Pax delivers tumor treating fields, which target the electrical properties of cancer cells, via wearable arrays.
The approval comes after a Phase 3 clinical trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival.
Shares soared 32% in premarket trading. Through the close, the stock was down 52% over the past 12 months.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.